Trial in Progress: Real-World Safety and Effectiveness of Brentuximab Vedotin in Adults with CD30+Lymphoma in China

被引：0
|
作者：
Xu, Pengpeng [1 ]
Cai, Mingci [1 ]
Zhang, Wendy [2 ]
Zhao, Wei Li [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med Shanghai, State Key Lab Med Genom, Shanghai Inst Hematol,Ruijin Hosp,Sch Med, Shanghai, Peoples R China
[2] Takeda China Int Trading Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-149031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4552
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching
    Phillips, Tycel J.
    Yu-Isenberg, Kristina
    Liu, Nicholas
    Surinach, Andy
    Flores, Carlos
    Lisano, Julie
    Fanale, Michelle A.
    Burke, John M.
    BLOOD, 2020, 136
  • [22] Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A plus CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression
    Jagadeesh, Deepa
    Sims, Robert B.
    Horwitz, Steven M.
    BLOOD, 2020, 136
  • [23] The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
    Xiaomeng Feng
    Wei Guo
    Yinping Wang
    Jia Li
    Yangzhi Zhao
    Limei Qu
    Xu Yan
    Junna Li
    Qiang Guo
    Ken. H. Young
    Ou Bai
    Advances in Therapy, 2022, 39 : 532 - 543
  • [24] Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.
    Feldman, Tatyana
    Zou, Denise
    Rebeira, Mayvis
    Lee, Joseph
    Harris, Mack
    Ma, Wenkang
    Fanale, Michelle A.
    Manley, Thomas John
    Feliciano, Joseph
    Rao, Shangbang
    Kansal, Anuraag
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany
    Zagadailov, Erin A.
    Corman, Shelby
    Chirikov, Viktor
    Johnson, Courtney
    Macahilig, Cynthia
    Seal, Brian
    Dalal, Mehul R.
    Broeckelmann, Paul J.
    Illidge, Tim
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1413 - 1419
  • [26] The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study
    Feng, Xiaomeng
    Guo, Wei
    Wang, Yinping
    Li, Jia
    Zhao, Yangzhi
    Qu, Limei
    Yan, Xu
    Li, Junna
    Guo, Qiang
    Young, Ken H.
    Bai, Ou
    ADVANCES IN THERAPY, 2022, 39 (01) : 532 - 543
  • [27] REAL-WORLD EFFECTIVENESS OF BRENTUXIMAB VEDOTIN (BV) VS OTHER TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RRHL) POST AUTOLOGOUS STEM-CELL TRANSPLANTATION (ASCT)
    Zagadailov, E. A.
    Corman, S.
    Hagan, M.
    Chirikov, V.
    Johnson, C.
    Macahilig, C.
    Dalal, M. R.
    Broeckelmann, P. J.
    HAEMATOLOGICA, 2016, 101 : 98 - 99
  • [28] Real-world outcomes of brentuximab vedotin maintenance after autologous stem cell transplant in relapsed/refractory classical Hodgkin lymphoma: Is less enough?
    Wagner, Charlotte Burton
    Ermann, Daniel Arthur
    Boucher, Kenneth M.
    Nedved, Adrienne
    Micallef, Ivana N. M.
    Hatic, Haris
    Goyal, Gaurav
    Hickey, Erin
    Fegley, Amanda
    Samuels, Courtney
    Kamdar, Manali K.
    Aqeel, Sheeba Habeeb Ba
    Torka, Pallawi
    MacDougall, Kira
    Borogovac, Azra
    Rajeeve, Sridevi
    Fedak, Kalub
    Travers, Elizabeth
    Shah, Harsh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data
    Sakellari, Ioanna
    Gavriilaki, Eleni
    Iskas, Michail
    Bousiou, Zoi
    Chatziioannidis, Aristotelis
    Batsis, I.
    Mallouri, Despina
    Constantinous, Varnavas
    Stavroyianni, Niki
    Syrigou, Antonia
    Marvaki, Anastasia
    Pilavaki, Maria
    Papaemmanouel, Styliani
    Anagnostopoulos, Achilles
    HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) : 490 - 492
  • [30] Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada
    Zou, Denise
    Lee, Joseph
    Kansal, Anuraag
    Ma, Wenkang
    Harris, Mack
    Lisano, Julie
    Fenton, Keenan
    Yu, Kristina S.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 324 - 333
12345